1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARDX. Le, Sarah B. Goldberg, Alessandro Morabito et al.|Journal of Thoracic Oncology|2025Cited by 22